International guest speaker, Dr Thomas Lönngren, Strategic Advisor, NDA Group AB and former Executive Director of the European Medicines Agency (EMA) is an expert on best practice for market access and regulatory strategy for biotech companies in the EU.
In this seminar, Thomas will provide attendees with an overview of the current European healthcare market and regulatory pathways to get to market. He will explore recent changes in the regulatory landscape; key developments in health technology assessments; and the essentials of payment and pricing in the EU.
Learn how your company can develop a robust EU strategy to alleviate risk and drive success in the European biotech market.
For a more in-depth look at this topic, you may be interested in participating in Module 5 of our Going Global Program – Pathways to Europe: Regulatory, commercial and market access for medicinal products.
Date: Tuesday 2 April
Time: 3.45 pm registration, presentation & discussion 4.00 pm – 5.00 pm, followed by networking until 6.00 pm
Venue: CBD location – TBA
BioMelbourne Network Members: $65
Non Members: $130
(Prices include GST.)
Note: Participants registered for the Going Global program will receive three registrations for this event.
A full refund is given up to 7 days prior to the event.
No refunds within 7 days of the event.
About our speaker
Dr Thomas Lönngren is the former Executive Director of the European Medicines Agency (EMA,2001–10) and previously served with the Swedish Board of Health and Welfare as Director of Operations (1978-93) and later Deputy Director General at the Swedish Medical Products Agency (MPA,(1993–2000). Thomas established the EMA from a relatively small unknown agency in 2001 to a world-renowned regulatory agency in 2010 and was responsible for all of its operations.
He is currently Director at his own independent consultancy, Pharma Executive Consulting UK (since Jan 2011) and PharmExec Consulting Filial SE (since July 2016) offering strategic advice to the health care, pharmaceutical and medical device sectors in the areas of Drug Development, Regulatory Affairs and Market Access. Through his consultancy, his main work is as Strategic Advisor at NDA Group AB.
Thomas is currently serving on several Advisory Boards and frequently speaks at conferences around the world. He is currently a board member of Global Kinetics Corporation in Melbourne Australia and Analytica Ltd in Brisbane Australia, and also is an advisor to Gerson Lehrman Group (GLG), The Centre for Innovation in Regulatory Science (CIRS), Scientificmed, Molecular Warehouse and ReNeuron.
He is Honorary Member of the Royal Pharmaceutical Society of Great Britain, Honorary Fellow of the Royal College of Physicians, Honorary Doctor of Uppsala University, Sweden and Honorary Doctor of the University of Bath, United Kingdom.